Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study

Abstract

Objective. Thymosin a-1 plus interferon a-2a offers superior efficacy over interferon a-2a alone in patients with chronic hepatitis B. The aim was to compare the antiviral efficacy of thymosin a-1 plus peginterferon a-2a and peginterferon a-2a alone in HBeAg-positive chronic hepatitis B patients. Materials and methods. HBeAg-positive CHB patients were enrolled in this prospective, randomized, open-label study. Fifty-one patients were assigned to either combination (26 patients; 180 mg of peginterferon a-2a weekly for 48 weeks and 1.6 mg of thymosin a-1 twice a week for the first 12 weeks) or monotherapy (25 patients; 180 mg of peginterferon a-2a weekly for 48 weeks) groups. Results. The rates of the combined response, defined as HBeAg seroconversion, HBV DNA suppression, and normalization of serum ALT, were 4/26 (15.4%) and 3/25 (12.0%) for the combination group and the monotherapy group at the end of treatment (p = 0.725), and 6/26 (23.1%) and 5/25 (20.0%) at the end of follow-up (p = 0.789), respectively. Based on multiple logistic regression analysis, a >2 log10 IU/mL reduction of HBV DNA at week 12 was identified as an independent predictor for combined response (OR, 9.72; 95% CI, 1.33–71.06; p = 0.025) at the end of follow-up. A lower pretreatment HBV DNA level (£7 log10 IU/mL) was another predictor for combined response (OR, 9.64; 95% CI, 1.23–75.32; p = 0.031). No significant differences in adverse events were observed. Conclusions. The short-term addition of thymosin a-1 was not superior to peginterferon a-2a alone in HBeAg-positive CHB patients on the basis of antiviral efficacy.